详细记录  
题名:Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
作者:Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Related Articles, Links
来源:Clin Cancer Res[IF=5.715]. 2007 Mar 15;13(6):1883-91.
URL :http://dx.doi.org/10.1158/1078-0432.CCR-06-2083
日期:070415
摘要: Yushe Dang1, Keith L. Knutson1, Vivian Goodell1, Corazon dela Rosa1, Lupe G. Salazar1, Doreen Higgins1, Jennifer Childs1 and Mary L. Disis1,2

1 Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, and 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Yushe Dang, Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, 815 Mercer Street, Box 358050, Seattle, WA 98109. Phone: 206-616-8447; Fax: 206-685-3128; E-mail: ydang@u.washington.edu.

Abstract

Purpose: Adoptive T-cell therapy is a promising strategy for the treatment of patients with established tumors but is often limited to specific cancers where tumor-infiltrating lymphocytes, the source of T cells for ex vivo culture, can be obtained. In this study, we evaluated the feasibility of expanding HER-2/neuCspecific T cells derived from peripheral blood ex vivo following in vivo priming with a HER-2/neu peptide vaccine.

Experimental Design: Peripheral blood mononuclear cells from cytomegalovirus (CMV)Cseronegative and CMV-seropositive donors as well as HER-2/neuCpositive cancer patients who had or had not been vaccinated with a HER-2/neu peptideCbased vaccine was used as a source of T lymphocytes. Antigen-specific T-cell lines were generated by in vitro stimulation with antigen followed by nonspecific expansion on CD3/CD28 beads. The ability to expand antigen-specific T cells was assessed using IFN- and granzyme B enzyme-linked immunosorbent spot. The phenotype of the resultant T-cell lines was evaluated by flow cytometry, including the presence of FOXP3-expressing CD4+ T cells.

Results: The frequencies of CMV-specific T cells generated from CMV+ donors were >11-fold higher than the frequencies from CMVC donors (P = 0.001), with 22-fold increase of total number of CD3+ T cells. The frequencies of HER-2/neuCspecific T cells generated from the primed patients were >25-fold higher than the frequencies from unvaccinated patients (P = 0.006), with an average of a 19-fold increase of total number of CD3+ T cells. Using peripheral blood as the source of T cells did not result in concurrent expansion of FOXP3+CD4+ regulatory T cells despite the use of interleukin-2 in in vitro culture. Both CD4+ and CD8+ HER-2/neuCspecific T cells could be expanded. The extent of ex vivo expansion correlated with the magnitude of immunity achieved during immunization (P = 0.008).

Conclusion: Tumor-specific T cells can be efficiently expanded from the peripheral blood ex vivo following in vivo priming with a vaccine. This approach provides an effective method to generate tumor-specific polyclonal T cells for therapeutic use that could be applied to cancer patients with any tumor type. 6:

================  评  论  部  分=================

重要性:
分类:(参照 Faculty of 1000 的分类体系)


评语:

评论密码:   返回前页  [全部]